Table 6

Multivariable Cox regression analyzing the association of bridging therapy use with progression-free survival (N=228)

VariableHR (95% CI)SEP value
Prior autologous stem cell transplant0.56 (0.34 to 0.94)0.150.029
ECOG performance status1.23 (0.97 to 1.55)0.150.084
LDH >500 (U/L, prior to CAR T-cell infusion)1.52 (0.89 to 2.59)0.410.122
CRP >30 (mg/L, prior to CAR T-cell infusion)2.01 (1.32 to 3.07)0.430.001
Bridging therapy use1.18 (0.77 to 1.82)0.260.449
Receipt of tocilizumab0.52 (0.34 to 0.80)0.110.003
CD28 co-stimulatory domain CAR T-cell product0.66 (0.37 to 1.17)0.190.158
  • CAR, chimeric antigen receptor; CRP, C-reactive protein; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase.